AMR

Life360 reports Q1 2024 results

Retrieved on: 
星期四, 五月 9, 2024
Churn, Total, Ship, Tile, Life360, Net, AMR, Yoy, ASX, Active users, Partnership, Growth, Documentation, Maus, MAU, Adjustment, RSU, Letter, SAN, Mobile phone

SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- San Francisco area-based Life360, Inc. (Life360 or the Company) (ASX: 360) today reported unaudited financial results for the quarter ended March 31, 2024.

Key Points: 
  • SAN FRANCISCO, May 9, 2024 /PRNewswire/ -- San Francisco area-based Life360, Inc. (Life360 or the Company) (ASX: 360) today reported unaudited financial results for the quarter ended March 31, 2024.
  • Life360 Co-founder and Chief Executive Officer Chris Hulls said: "Life360's Q1'24 results showed continued momentum, with net Paying Circles additions nearly doubling to 96 thousand from 54 thousand in Q4'23, achieving a new first quarter record.
  • "Last quarter we introduced a new advertising offering which is now live in production with U.S. members and early results are promising.
  • The Australia and New Zealand triple-tier membership launched in late April 2024, following a price increase for existing subscribers.

EQS-News: Stabilus SE closes Q2 FY2024 with a slight increase in revenue

Retrieved on: 
星期五, 五月 10, 2024
CFO, WKN, FCF, Motivation, AMR, Machine industry, IMA, Commercial vehicle, Environment, Recreation, Acquisition, Distributor, Interim, Adjustment, HRF, Growth, Video game

Group revenue in the second quarter of FY2024 increased by 0.9% to €313.5 million compared to the same quarter of the previous year (Q2 FY2023: €310.6 million).

Key Points: 
  • Group revenue in the second quarter of FY2024 increased by 0.9% to €313.5 million compared to the same quarter of the previous year (Q2 FY2023: €310.6 million).
  • From the beginning of the third quarter of 2024, DESTACO will thus contribute to the Stabilus Group's revenue and earnings.
  • In the EMEA region, revenue increased by 0.2% to €137.5 million in Q2 FY2024 (Q2 FY2023: €137.2 million).
  • Adjusted operating profit (adjusted EBIT[1]) decreased by 4.7% to €38.9 million in Q2 FY2024 (Q2 FY2023: €40.8 million).

Himax Technologies, Inc. Reports First Quarter 2024 Financial Results; Provides Second Quarter 2024 Guidance

Retrieved on: 
星期四, 五月 9, 2024
System, Artificial intelligence of things, Risk, AI, Partnership, OEM, Signal-to-noise ratio, OLED, FHD, Face, Automatic meter reading, LCD, Traction, ICS, EV, Tablet, GM, Season, Algorithm, Ecosystem, Display, Public expenditure, EPS, DB, Liquid crystal on silicon, Quarter, DSO, CMOS, AMR, CNN, Smartphone, ADS, Environment, Growth, Video game

TAINAN, Taiwan, May 09, 2024 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, announced its financial results for the first quarter 2024 ended March 31, 2024.

Key Points: 
  • Himax net revenues registered $207.6 million, a decrease of 8.8% sequentially, exceeding its guidance range of a 9% to 16% decline.
  • Sales of large panel driver ICs accounted for 15.1% of total revenues for the quarter, compared to 14.8% last quarter and 21.7% a year ago.
  • First quarter revenues from its non-driver business exceeded guidance, reaching $32.0 million, an increase of 3.4% from the previous quarter.
  • As of March 31, 2024, Himax had 174.7 million ADS outstanding, unchanged from last quarter.

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 9, 2024
MuSK protein, FDA, ARDA, IND, PDUFA, Medicine, Autoimmunity, Efgartigimod alfa, Glomerulonephritis, CMS, Inflammation, ITP, IIP, ALS, Alfa Romeo, C2, Therapy, Systemic scleroderma, Safety, Euronext, Nektar, DGF, Sjögren syndrome, CIDP, Biology, IL-6, Nektar Therapeutics, GMG, TED, File, MMN, Lupus nephritis, Kidney, AMR, Multifocal motor neuropathy, Patient, Congenital myasthenic syndrome, Immune system, Dermatomyositis, Growth, Amgen, Pharmaceutical industry

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • “We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy.
  • VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Seven Additional Private Sector Leaders Announce Support for Antimicrobial Use Stewardship Principles in Poultry, Now Includes Over 40% of Global Poultry Meat Production

Retrieved on: 
星期三, 五月 8, 2024
Agriculture, Natural Resources, Pharmaceutical, Health, Infectious Diseases, Supply Chain Management, Food, Beverage, Retail, CPEP, Mortality, Poultry, IPC, Risk, Heifer International, Animal, Global health, AMR, Antimicrobial stewardship, BPC, Cargill, Research, Farmer, ALA, VIPA, Disease, Human, Zoonosis, Tyson Foods, ABPA, International development, TFC, CFC, Multimedia, Infection, Private sector, Diagnosis, PFI, British Poultry Council, Organization, USAID, TBA

By generating support from the global poultry industry of science-based principles to address antimicrobial use, the industry is acting to combat AMR and reduce its impact on global health security.

Key Points: 
  • By generating support from the global poultry industry of science-based principles to address antimicrobial use, the industry is acting to combat AMR and reduce its impact on global health security.
  • These seven organizations join 19 other organizations in endorsing or adopting antimicrobial use stewardship principles that reduce the need to use antimicrobials at the farm level.
  • “By proactively supporting science-based antimicrobial use principles, the private sector is sending a clear message that antimicrobial stewardship is good business,” said Ricardo Santin, IPC President.
  • TRANSFORM’s research portfolio includes 22 trials to study the impact of animal nutrition on priority pathogens and antimicrobial resistant genes.

Körber Named a Leader in 2024 Gartner® Magic Quadrant for Warehouse Management Systems for Sixth Consecutive Year

Retrieved on: 
星期三, 五月 8, 2024
Technology, Transport, Other Technology, Software, Robotics, Electronic Design Automation, Logistics, Supply Chain Management, Retail, Completeness, Ability, Publication, AMR, REWE, Research, Warehouse control system, Human, Human voice, Customer, WMS, WCS, Magic Quadrant, Warehouse

As companies scramble to address rising consumer expectations, effective supply chain technology is of vital importance. Körber’s WMS solutions make it possible to meet and exceed their outcomes across all levels of complexity and scale, by catering to the unique needs of small businesses, global enterprises and third-party logistics providers, all driving to meet end consumer expectations. Körber’s comprehensive suite of supply chain solutions combine to ensure businesses have the technology at their fingertips to revolutionize the end-to-end supply chain--from source to doorstep delivery.

Key Points: 
  • Körber , a global provider of warehouse management system (WMS) solutions, announced today that it has been positioned as a Leader for its Completeness of Vision and Ability to Execute in the 2024 Gartner Magic Quadrant for Warehouse Management Systems report again this year.
  • Körber was also recently acknowledged in the 2023 Gartner® Peer Insights™ Voice of the Customer for Warehouse Management Systems (WMS) .
  • Placed in the upper-right corner of the “Voice of the Customer” grid, Körber was recognized as a Gartner Peer Insights Customers’ Choice.
  • *Source: Gartner, “2024 Magic Quadrant for Warehouse Management Systems,” Simon Tunstall, Dwight Klappich, Rishabh Narang, Federica Stufano 2 May 2024.

Global Health Leaders Unite to Confront Urgent Public Health Crisis of Antimicrobial Resistance

Retrieved on: 
星期二, 五月 7, 2024
Public Policy, Government, Other Communications, General Health, Health, Other Policy Issues, Infectious Diseases, Communications, Public, Cancer, Antimicrobial resistance, Social isolation, Pathogenic bacteria, Risk, Malaria, CDC, Animal, AMR, Death, Biotechnology Innovation Organization, Parent, Research, BIO, Plant, Friends, Environment, Human, Partnership, Disease, Family, JD, Patient, Caregiver, Face, Diary, Child, HIV, Infection, Associate, TB, COVID-19, Diplomatic rank, Pharmaceutical industry

Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.

Key Points: 
  • Awareness that is desperately needed because significant worldwide efforts to date have yet to penetrate global consciousness about this public health emergency.
  • "Antimicrobial resistance is an urgent global public health threat that poses risks to modern medicine, the health of humans, animals, plants, the environment, and the global economy.
  • These stories are poised to transform the AMR crisis from a distant concept to a relatable and urgent reality.
  • Putting a human face on this global emergency is critical to motivating action that can change the course of this escalating health crisis.

KION North America and Fox Robotics Announce Non-Exclusive Strategic Partnership

Retrieved on: 
星期二, 五月 7, 2024
Technology, Venture Capital, Transport, Professional Services, Manufacturing, Machinery, Logistics, Supply Chain Management, Retail, Artificial Intelligence, Investment, KION, Safety, KUKA, Linde, AMR, Robotics, Traction, Partnership, KION Group, Automation, BMW, Face, Multimedia, Menlo Ventures, Algorithm, Growth, Rail freight transport

KION North America (KION NA), manufacturer of Linde Material Handling equipment, and Fox Robotics have entered into a non-exclusive partnership wherein KION NA will manufacture and assemble FoxBot autonomous trailer loader/unloaders (ATLs) at its facilities in Summerville, South Carolina.

Key Points: 
  • KION North America (KION NA), manufacturer of Linde Material Handling equipment, and Fox Robotics have entered into a non-exclusive partnership wherein KION NA will manufacture and assemble FoxBot autonomous trailer loader/unloaders (ATLs) at its facilities in Summerville, South Carolina.
  • View the full release here: https://www.businesswire.com/news/home/20240507592176/en/
    KION North America (KION NA), manufacturer of Linde Material Handling equipment, and Fox Robotics have entered into a non-exclusive partnership wherein KION NA will manufacture and assemble FoxBot autonomous trailer loader/unloaders (ATLs) at its facilities in Summerville, South Carolina.
  • “We are delighted to announce our collaboration with Fox Robotics to launch this groundbreaking product in the U.S. market.
  • This partnership signifies a major leap forward in our commitment to enhancing efficiency, safety, and reliability in our customers' operations.”
    "Fox Robotics is scaling and expanding its supply chain capabilities significantly via the partnership with KION North America," said Marin Tchakarov, CEO and President at Fox Robotics.

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
星期一, 五月 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
星期一, 五月 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."